Educational reference only

Tirzepatide is a prescription medication in most countries. This page is for educational reference only. Underground Biohacking does not provide dosing protocols, interaction warnings, or usage guidance for prescription compounds. If you are using or considering Tirzepatide, work with a licensed clinician.

Metabolic

Tirzepatide

Name: Tirzepatide
Creator: Chris Hallewell

By Chris Hallewell, Founder, Underground Biohacking

Last reviewed 6 August 2026

Prescription only

Tirzepatide is an approved prescription medicine, not a research chemical. The FDA cleared it as Mounjaro for type 2 diabetes and as Zepbound for weight management. Zepbound is also approved for moderate to severe obstructive sleep apnoea in adults with obesity. The evidence here is human and unusually large. The SURPASS and SURMOUNT trial programmes ran for years in thousands of people. They show big drops in weight and blood sugar. Gut side effects are common, and gallbladder problems are raised.

What is Tirzepatide?

Tirzepatide is a synthetic peptide, a short chain of amino acids made in a lab. It is built to copy two gut hormones at once. The first is GIP (glucose-dependent insulinotropic polypeptide). The second is GLP-1 (glucagon-like peptide-1). Your gut releases both after you eat. They tell the pancreas to release insulin and tell the brain that you have had enough. Almost every other drug in this family copies GLP-1 alone. Tirzepatide switches on both receptors, so it is called a dual agonist. That is the whole design idea. It is also why researchers ran it head to head against semaglutide, which is GLP-1 only, in people with type 2 diabetes. The molecule is modified so it stays in the blood far longer than a natural gut hormone. A real gut hormone is cleared in minutes. Tirzepatide lasts long enough to be given as a weekly injection under the skin. That matters for how it is studied and prescribed. It is not a supplement and not a grey market research peptide. It is a prescription drug with an FDA reviewed label, and a doctor decides whether it fits you.

What is Tirzepatide prescribed for?

In people with moderate to severe obstructive sleep apnoea and obesity, tirzepatide cut the number of breathing pauses per hour of sleep.^[1]Human study
In people with obesity and prediabetes, three years of tirzepatide kept weight down and cut the risk of developing type 2 diabetes.^[3]Human study
In people with obesity and type 2 diabetes, far more lost at least five percent of their body weight on tirzepatide than on placebo.^[6]Human study
In people with type 2 diabetes, tirzepatide lowered long term blood sugar more than semaglutide over forty weeks.^[5]Human study
In people whose type 2 diabetes was managed by diet and exercise alone, tirzepatide improved blood sugar and weight without causing low blood sugar.^[4]Human study
In people with type 2 diabetes and a fatty liver, tirzepatide cut liver fat and belly fat more than insulin degludec did.^[7]Human study
In people with obesity and heart failure with a preserved ejection fraction, tirzepatide lowered the risk of worsening heart failure or cardiovascular death.^[8]Human study

How does Tirzepatide work?

Tirzepatide activates two receptors. It hits the GLP-1 receptor, like semaglutide, and it also hits the GIP receptor. GIP is a second gut hormone released with meals. Both receptors sit on insulin-making cells and in brain regions that set appetite, so the two signals overlap. Adding GIP appears to sharpen the insulin response and cut food intake further. What GIP actually contributes is still argued. Blocking the GIP receptor alongside GLP-1 also drives weight loss, and nobody has fully explained why. Tirzepatide carries the same albumin-binding trick, so it stays in your blood a long time.

Educational reference only. Talk to a licensed clinician for any decisions on Tirzepatide.

What are the side effects of Tirzepatide?

Effect	How serious	What to watch
Gut side effects are the main problem. Nausea, diarrhoea and vomiting were the most reported events in trials.^[5]	Common, mostly mild to moderate	Nausea, vomiting, diarrhoea, and signs you are getting dehydrated
Those gut symptoms cluster early, in the weeks when the amount given is being stepped up.^[2]	Common, mostly mild to moderate	Whether symptoms settle once the early weeks pass
Gallbladder and bile duct problems came up more often on tirzepatide than on placebo or insulin.^[9]	Uncommon, but a real signal	Pain in the upper right belly, fever, yellow skin or eyes
Pancreatitis was looked for across the trials and no increase was found.^[9]	No raised risk seen so far	Severe belly pain that will not ease and spreads to your back
Some people stop treatment because of side effects, mainly gut ones.^[8]	Uncommon, but higher than placebo	Whether side effects are bad enough to affect eating or daily life

Is Tirzepatide legal in 2026?

Checked on 6 August 2026. Tirzepatide is an FDA approved prescription medicine, not a research compound. It is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management. On 20 December 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnoea in adults with obesity. It is used with a reduced calorie diet and more activity. That was the first drug ever approved for that condition. Both products are prescription only. The FDA has separately warned about unapproved and compounded versions of GLP-1 drugs, tirzepatide included. It says those versions are not reviewed for safety, effectiveness or quality before they are sold, and it has flagged fraudulent labels and dosing errors.

Status checked 6 August 2026 against the primary source.

Educational reference only. Talk to a licensed clinician for any decisions on Tirzepatide.

If you are considering Tirzepatide

This page does not provide dosing, cycling, stacking, or sourcing guidance for Tirzepatide. The protocol conversation belongs with a licensed clinician who can review your bloodwork, history, and goals.

Where to buy Tirzepatide

Running Tirzepatide in your next protocol cycle?

Check out our recommended sources list to find vetted vendors you can trust.

View sources

Frequently Asked Questions

Is tirzepatide a research peptide or a real approved medicine?

It is a real approved medicine. The FDA approved it as Mounjaro for type 2 diabetes and as Zepbound for weight management. Zepbound is also approved for moderate to severe obstructive sleep apnoea in adults with obesity. That puts it in a different category from most peptides written about online. It has a reviewed label, published phase 3 trials, and a known safety profile. It is prescription only, so a doctor has to decide it fits you.

What did the obesity trials actually show?

They showed large, sustained weight loss in people, not in mice. Take adults with obesity and type 2 diabetes. Most people on tirzepatide lost at least five percent of their body weight, against about a third on placebo. A separate three year trial ran in people with obesity and prediabetes. Weight stayed down, and far fewer went on to develop type 2 diabetes. These were randomised, placebo controlled trials with thousands of participants.

Can it treat obstructive sleep apnoea?

Yes, and this is now an approved use. Two phase 3 trials enrolled adults with moderate to severe obstructive sleep apnoea and obesity. One trial enrolled people using a breathing machine at night, one enrolled people who were not. In both, tirzepatide cut the number of breathing pauses per hour of sleep, along with body weight, oxygen dips, inflammation and blood pressure. Sleep related symptoms improved too. The benefit is thought to follow from the weight loss.

How does it compare with semaglutide?

They were compared directly in people with type 2 diabetes over forty weeks. Tirzepatide lowered long term blood sugar more than semaglutide, and it produced more weight loss. Gut side effects were similar in both groups, mostly mild to moderate. The likely reason for the difference is design: semaglutide copies one gut hormone, tirzepatide copies two. That said, this was one trial in one population, and the better option for any individual is a clinical judgement.

What are the most common side effects?

Gut trouble, by a wide margin. Nausea, diarrhoea and vomiting were the most reported events across the trials. Most were mild to moderate, and they clustered in the early weeks while the amount given was being stepped up. A small share of people stopped treatment because of them. Gallbladder and bile duct problems showed up more often than on placebo. Pancreatitis was looked for in a pooled analysis and no increase was found.

What should I ask a doctor before starting?

Ask whether your reason for wanting it matches an approved use, and what the realistic result looks like for you. Ask about your thyroid and pancreas history, and about gallbladder symptoms, since biliary problems came up more often in trials. Ask how the early gut side effects will be handled. Ask what other medicines you take might interact. Ask what happens if you stop, and how progress will be checked over time.

References

1.Malhotra A, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine. PMID: 38912654. DOI: 10.1056/NEJMoa2404881.
2.Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.
3.Jastreboff AM, et al. (2024). Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. PMID: 39536238. DOI: 10.1056/NEJMoa2410819.
4.Rosenstock J, et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). PMID: 34186022. DOI: 10.1016/S0140-6736(21)01324-6.
5.Frias JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine. PMID: 34170647. DOI: 10.1056/NEJMoa2107519.
6.Garvey WT, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). PMID: 37385275. DOI: 10.1016/S0140-6736(23)01200-X.
7.Gastaldelli A, et al. (2022). Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. The lancet. Diabetes & endocrinology. PMID: 35468325. DOI: 10.1016/S2213-8587(22)00070-5.
8.Packer M, et al. (2024). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. PMID: 39555826. DOI: 10.1056/NEJMoa2410027.
9.Zeng Q, et al. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in endocrinology. PMID: 37908750. DOI: 10.3389/fendo.2023.1214334.

One more time, because it matters

This page exists to identify Tirzepatide and explain what the research describes. Underground Biohacking does not advise on dosage, cycling, stacking, or where to source prescription compounds. If Tirzepatide is part of your plan, that conversation belongs with a clinician who can review your labs, history, and goals. Not with a website.